University of Groningen

The epidermal growth factor receptor pathway in relation to pelvic lymph node metastasis and survival in early-stage cervical cancer

Eijsink, J.J.; Noordhuis, M.G.; Ten Hoor, K.A.; Kok, M.; Hollema, Harry; de Bock, Gertruida H; Nijman, Hans; Schuuring, Eduardus; Wisman, G.B.A.; van der Zee, Ate

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version
Publisher's PDF, also known as Version of record

[Link to publication in University of Groningen/UMCG research database](#)

Original contribution

The epidermal growth factor receptor pathway in relation to pelvic lymph node metastasis and survival in early-stage cervical cancer

Jasper J. H. Eijsink MD[a], Maartje G. Noordhuis[a], Klaske A. ten Hoor[a], Mirjam Kok[a], Harry Hollema MD, PhD[b], Geertruida H. de Bock PhD[c], Hans W. Nijman MD, PhD[a], Ed Schuuring PhD[b], G. Bea A. Wisman PhD[a], Ate G. J. van der Zee MD, PhD[a],*

[a]Department of Gynaecologic Oncology, University Medical Center Groningen, University of Groningen, PO Box 30001, 9700 RB Groningen, The Netherlands
[b]Department of Pathology, University Medical Center Groningen, University of Groningen, PO Box 30001, 9700 RB Groningen, The Netherlands
[c]Department of Epidemiology, University Medical Centre Groningen, University of Groningen, Groningen, PO Box 30001, 9700 RB Groningen, The Netherlands

Summary The objective of this study is to correlate the expression of epidermal growth factor receptor (EGFR) components with clinical behavior of early-stage cervical cancer. Tissue samples of 336 consecutive Federation of International Gynecologists and Obstetricians stage IB-IIA cervical cancer patients all treated primarily by radical surgery were collected. Clinicopathologic and follow-up data were prospectively obtained during standard treatment and follow-up. As representatives for the EGFR pathway, expression of EGFR, pEGFR, PTEN, pAKT, and pERK was assessed by immunohistochemistry on tissue microarrays. Positive immunostaining was observed for EGFR in 32.1%, for pEGFR in 21.0%, for PTEN in 38.3%, for pAKT in 5.3%, and for pERK in 4.3% of tumor samples. Positive EGFR immunostaining was associated with squamous cell carcinoma of the cervix (odds ratio [OR], 7.41; 95% confidence interval [CI], 3.38-16.23, $P < .001$), negative pEGFR immunostaining with poor differentiation (OR, 0.39; 95% CI, 0.20-0.73, $P = .004$), and negative PTEN immunostaining with metastatic pelvic lymph nodes (OR, 0.51; 95% CI, 0.30-0.90, $P = .019$). In multivariate analysis, only pelvic lymph node metastasis (hazard ratio, 6.11; 95% CI, 3.46-10.77, $P < .001$) and poor differentiation (hazard ratio, 1.91; 95% CI, 1.12-3.26, $P = .018$) were related to disease-specific survival. In early-stage cervical cancer, loss of PTEN expression is associated with pelvic lymph node metastasis, suggesting PTEN to be one of the tumor suppressor genes affecting pelvic lymph node metastasis. However, expression of EGFR pathway components does not appear to have prognostic impact in surgically treated early-stage cervical cancer.
© 2010 Elsevier Inc. All rights reserved.

* Corresponding author.
 E-mail address: a.g.j.van.der.zee@og.umcg.nl (A. G. J. van der Zee).

1. Introduction

Early-stage cervical cancer is generally treated by radical hysterectomy and pelvic lymph node dissection. In cases with poor clinicopathologic factors, adjuvant radiotherapy with or without chemotherapy is often administered. Conventional prognostic factors in early-stage cervical cancer are tumor size, depth of stromal invasion, lymphovascular space involvement, parametrial invasion, and pelvic lymph node metastasis [1-4]. Pelvic lymph node metastasis appears to be the most important of these parameters [5], with a 5-year survival approximating 90% in node-negative early-stage cervical cancer patients primarily treated with surgery and decreasing to approximately 65% in patients with pelvic lymph node metastasis [6]. In early-stage cervical cancer, molecular markers could be helpful in selecting lymph node–negative patients with an unfavorable prognosis for adjuvant treatment and might identify new targets for patient-tailored therapy.

The epidermal growth factor receptor (EGFR) is involved in the ErbB signaling network, which is often deregulated in cancer. Autophosphorylation of EGFR to pEGFR leads to activation of the Ras/Raf/MEK/ERK pathway and the phosphoinositide 3-kinase (PI3K)/AKT pathway, both of which are involved in processes that are associated with carcinogenesis and tumor progression, such as inhibition of apoptosis, cell migration, cell growth, and angiogenesis [7]. PTEN (phosphatase and tensin homolog deleted on chromosome 10) acts as a tumor suppressor gene by inhibiting phosphorylation and thereby activation of AKT [8,9]. Only few data, obtained in small series of cervical cancer patients primarily treated by surgery, exist on EGFR or PTEN expression [10-13], and no published studies provide a comprehensive analysis of several EGFR pathway components simultaneously in a well-defined series of early-stage cervical cancer patients.

Previous studies of molecular markers in early-stage cervical cancer have been limited by the small number of patients evaluated and/or mediocre documentation of clinicopathologic parameters. The present study was designed to correlate expression of EGFR, pEGFR, PTEN, pAKT, and pERK in relation to clinicopathologic parameters and disease-specific survival in a large, well-documented series of patients with early-stage cervical cancer and long-term follow-up.

2. Materials and methods

2.1. Patients and treatment

Since 1980, clinicopathologic characteristics and follow-up data of all cervical cancer patients referred to the Department of Gynaecologic Oncology of the University Medical Center Groningen, the Netherlands, have been prospectively entered into a computerized database. Clinical staging of each patient is performed under general anesthesia in accordance with the Federation of International Gynecologists and Obstetricians (FIGO) criteria. For the present study, we selected all early-stage cervical cancer patients, treated primarily by surgery between January 1980 and December 2004 from our database (n = 336). All patients underwent type 3 radical hysterectomy and pelvic lymph node dissection. Patients with pelvic lymph node metastases, parametrial invasion, or positive excision margins received adjuvant external beam radiotherapy with or without chemotherapy. Paraffin-embedded formalin-fixed primary tumor tissue was collected from each patient. Patients were only included in our analysis if sufficient representative tumor tissue was available for tissue microarray (TMA) construction. After completion of treatment, patients were followed up at the outpatient clinic for at least 5 years.

2.2. Institutional review board approval

In the University Medical Center Groningen, clinicopathologic and follow-up data are prospectively obtained during standard treatment and follow-up and stored in a computerized registration database. For the present study, all relevant data were retrieved from this computerized database into a separate, anonymous database. Patient identity was protected by study-specific, unique patient numbers. Codes were only known to 2 dedicated data managers, who also have daily responsibility for the larger database. In case of uncertainties with respect to clinicopathologic and follow-up data, the larger databases could only be checked through the data managers, thereby ascertaining the protection of patients' identity. Using the registration database, we identified all tissue specimens by unique patient numbers and retrieved them from the archives of the Department of Pathology. Therefore, according to Dutch law, no further Institutional Review Board approval was needed for this study (http://www.federa.org/).

2.3. Tissue microarray construction

As previously described, representative areas of tumor were marked on hematoxylin and eosin–stained slides of the paraffin-embedded tissue [14]. Areas of necrosis and/or heavy leukocytic infiltrate were avoided. The TMAs were constructed using a precision instrument (Beecher Instruments, Silver Spring, MD). Three 0.6 mm in diameter cores were punched from the marked area of the paraffin-embedded tissue (donor block) and transferred to a predefined location in a blank paraffin block (recipient block). After all the cores had been inserted, the recipient block was placed in an oven of 37°C for 15 minutes to attach the cores to the surrounding paraffin. Each TMA also contained benign (skin epithelia, normal cervical tissue, and colon polyps) and tumor (breast, colon and ovarian carcinoma) tissue that served as controls

for immunostaining and comparison of TMAs. In total, 5 TMAs were constructed.

2.4. Immunohistochemistry

For immunohistochemistry, 4-μm sections were cut from the TMA and mounted on amino-propyl-ethoxy-silan (Sigma-Aldrich, Diessenhofen, Germany)–coated glass slides. Immunohistochemistry for EGFR, pEGFR, PTEN, pAKT, and pERK was performed as described previously [15]. Details of the antibodies used for immunohistochemistry and methods for antigen retrieval are summarized in Table 1. The avidin-biotin-peroxidase method was used for all antibody detection, except pAKT for which the EnVision horseradish peroxidase system (Dako, Copenhagen, Denmark) was used. Slides were deparaffinized in xylene and rehydrated in ethanol. Endogenous peroxidase was blocked by incubation with 0.3% hydrogen peroxidase for 30 minutes. For staining in which the avidin-biotin-peroxidase method was used, endogenous avidin and biotin activity was blocked using a blocking kit (Vector Laboratories, Burlingame, UK). Immunostaining was visualized by 3′ 3-diaminobenzidine tetrahydrochloride, and counter immunostaining was performed with hematoxylin.

2.5. Evaluation of immunostaining

Scoring was performed by 2 independent observers (JJHE and MGN) without knowledge of clinical data. A concordance of more than 90% was found. The discordant cases were reviewed, and scores were reassigned on consensus. Immunostaining intensity was semiquantitatively scored. Only patients with at least 2 representative cores were included in the analysis. Tumors were considered positive for EGFR when more than 10% positive membranous immunostaining was observed [12]. pAKT and pERK immunostaining were considered positive if more than 10% of a tumor showed cytoplasmic and/or nuclear immunostaining [15]. Positive expression of PTEN was defined as more than 10% cytoplasmic immunostaining [16]. Positive pEGFR was defined as at least weak positive cytoplasmic immunostaining, as the activated EGFR is internalized [17].

2.6. Statistical analysis

Statistical analysis was performed with SPSS 16.0 for Windows (SPSS Inc, Chicago, IL). Associations (odds ratios [ORs] and 95% confidence interval [CI]) between immunostaining intensity and clinicopathologic characteristics were assessed in a univariate logistic regression model using positive protein expression as dependent factor and the clinicopathologic characteristics as independent factors. Relations (hazard ratios [HR] and 95% CI) between disease-specific survival, clinicopathologic features, and immunostaining were calculated using both univariate and multivariate Cox proportional hazard analysis. In these analyses, factors with a P value greater than .10 in the univariate analyses were excluded stepwise in multivariate analyses. P values of less than .05 were considered statistically significant.

3. Results

3.1. Patients and tumor characteristics

In total, 336 patients diagnosed with early-stage cervical cancer (IB1: n = 221 [66%]; IB2: n = 63 [19%]; IIA: n = 52 [15%]) and treated by radical hysterectomy and pelvic lymph node dissection were identified. In 310 cases, sufficient pretreatment tissue was available for TMA construction. Median age was 43 years (range, 17-86 years), and median follow-up time was 5.5 years (range, 0.31-18.60 years). Overall, 5-year disease-specific survival for the 310 patients was 82.4%. Additional patient and tumor characteristics are summarized in Table 2.

3.2. Clinicopathologic factors in relation to EGFR, pEGFR, PTEN, pAKT, and pERK

The proportion of patients included in the analysis based on 2 or more representative cores was 93.5% for EGFR, 93.5% for pEGFR, 91.0% for PTEN, 90.7% for pAKT, and 89.1% for pERK. Fig. 1 shows a representative negative and

Table 1	Antibodies used for immunostaining				
Antigen	Antigen retrieval	Clone	Company	Dilution	Incubation time
PTEN	Citrate (pH 6) [a]	6H2.1	Cascade [b]	1:100	60 min
EGFR	Proteinase K 0.1%, 30 min	111.6	Neomarkers [c]	1:200	60 min
pEGFR	EDTA (pH 8) [a]	1H12	Cell Signaling [d]	1:200	60 min
pAKT 1/2	Citrate (pH 6) [a]	736E11	Cell Signaling [d]	1:50	Overnight (4°C)
pERK 1/2	Citrate (pH 6) [a]	20G11	Cell Signaling [d]	1:50	Overnight (4°C)

[a] Sections were boiled in a microwave for 15 minutes.
[b] Cascade Bioscience, Winchester, MA.
[c] Neomarkers, Lab Vision Corporation, Fremont, CA.
[d] Cell Signaling, Danvers, MA.

Table 2 Patients and tumor characteristics

	N = 310
	n (%)
FIGO stage	
IB1	197 (64%)
IB2	63 (20%)
IIA	50 (16%)
Treatment	
WM	188 (61%)
WM + radiotherapy	106 (34%)
WM + chemoradiotherapy	16 (5%)
Tumor type	
Squamous carcinoma	200 (65%)
Adenocarcinoma	87 (28%)
Other	23 (7%)
Differentiation grade	
Good/moderate	180 (58%)
Poor	124 (40%)
Unknown	6 (2%)
Lymphangioinvasion	
Yes	160 (52%)
No	149 (48%)
Unknown	1 (0%)
Depth of invasion	
0-10 mm	165 (53%)
≥10 mm	131 (42%)
Unknown	14 (5%)
Margins	
Negative	299 (96%)
Positive	11 (4%)
Lymph nodes	
Negative	222 (72%)
Positive	88 (28%)
Tumor diameter	
0-4 cm	223 (72%)
≥4 cm	87 (28%)
Recurrence	
No	245 (79%)
Local-regional	38 (13%)
Distance	14 (5%)
Progression	4 (1%)
Unknown	9 (5%)

Abbreviation: WM = Wertheim-Meigs.

Fig. 1 Tumor microarray stained for EGFR, pEGFR, PTEN, pAKT, and pERK (100×). Negative staining (A, C, E, G, and I). Positive staining (B, D, F, H, and J).

positive core for each staining. Positive EGFR immunostaining was observed in 93 (32.1%) of 290 patients, positive pEGFR immunostaining in 61 of 290 (21.0%) patients, positive PTEN immunostaining in 108 (38.3%) of 282 patients, positive pAKT immunostaining in 15 (5.3%) of 281 patients, and positive pERK immunostaining in 12 (4.3%) of 276 patients. Positive pEGFR immunostaining correlated with PTEN (OR, 2.454; 95% CI, 1.367-4403, P = .003) and with pERK (OR, 4.468; 95% CI, 1.380-14.468, P = .013). No additional correlations between the immunostains were found (data not shown).

Table 3 shows clinicopathologic features in relation to immunostaining. Positive membranous immunostaining for

EGFR was associated with squamous cell carcinoma of the cervix (OR, 7.41; 95% CI, 3.38-16.23, P < .001), negative pEGFR cytoplasmic immunostaining was associated with

Table 3 Clinicopathologic parameters and immunostaining

	EGFR positive			pEGFR positive			PTEN positive			pAKT positive			pERK positive		
	OR	95% CI	P	OR	95% CI	P	OR	95% CI	P	OR	95% CI	P	OR	95% CI	P
Age	1.00	0.99-1.02	.747	1.02	0.99-1.04	.117	1.00	0.98-1.01	.630	1.02	0.99-1.06	.248	0.99	0.94-1.03	.550
Stage ≥IB2	1.37	0.83-2.27	.222	0.87	0.48-1.58	.653	0.73	0.44-1.21	.221	2.02	0.71-5.75	.186	0.14	0.02-1.10	.062
Squamous	7.41	3.38-16.23	<.001	1.41	0.73-2.75	.325	1.76	0.99-3.10	.052	2.33	0.50-10.75	.280	0.61	0.17-2.22	.452
Poor differentiation	0.75	0.45-1.25	.273	0.39	0.20-0.73	.004	0.66	0.40-1.09	.102	0.74	0.25-2.24	.597	0.73	0.22-2.50	.620
Lymphangioinvasion	1.18	0.72-1.94	.517	0.99	0.56-1.75	.967	0.83	0.51-1.34	.445	1.02	0.36-2.90	.970	0.66	0.20-2.12	.483
Infiltration depth ≥10 mm	1.50	0.90-2.49	.120	0.78	0.43-1.40	.407	0.61	0.37-1.01	.053	0.38	0.12-1.23	.106	0.85	0.26-2.73	.778
Positive lymph nodes	1.62	0.95-2.75	.077	1.20	0.66-2.21	.547	0.51	0.30-0.90	.019	0.58	0.16-2.12	.410	0.83	0.22-3.13	.777
Tumor diameter ≥4 cm	1.36	0.80-2.34	.260	0.81	0.42-1.54	.513	0.73	0.42-1.25	.247	1.30	0.43-3.92	.645	0	0	.997

poor differentiation (OR, 0.39; 95% CI, 0.20-0.73, $P = .004$), and negative PTEN immunostaining was associated with metastatic pelvic lymph nodes (OR, 0.51; 95% CI, 0.30-0.90, $P = .019$).

3.3. EGFR, pEGFR, PTEN, pAKT, and pERK and disease-specific survival

In univariate Cox regression analysis, none of the immunostain results correlated with disease-specific survival (Table 4). In multivariate Cox regression analysis, only positive lymph nodes (HR, 6.11; 95% CI, 3.46-10.77, $P < .001$) and poor differentiation (HR, 1.91; 95% CI, 1.12-3.26, $P = .018$) were independent prognostic factors for disease-specific survival.

4. Discussion

Immunohistochemical expression of EGFR pathway components EGFR, pEGFR, PTEN, pAKT, and pERK was evaluated in relation to clinicopathologic parameters and disease-specific survival in a consecutive series of early-stage cervical cancer patients. Our study indicates that loss of PTEN expression frequently occurs in early-stage cervical cancer and is related to pelvic lymph node metastasis (OR, 0.51; 95% CI, 0.30-0.90, $P = .019$), but not to survival. Only limited data exist on PTEN expression and its possible implications for the biologic behavior of cervical cancer. In a study by Lee et al [13], reduced PTEN expression was identified in 17.6% (15/85) of surgically treated cervical cancer patients and was associated with decreased disease-free and overall survival, but not with pelvic lymph node metastasis. They reported a gradual reduction of PTEN expression along the continuum from normal epithelium through intraepithelial neoplasia to squamous cell carcinoma. Discrepancies between the data from Lee et al [13] and our study might be due to the number of evaluated patients (n = 85 vs n = 310) and/or interpretation of immunostaining, because Lee et al defined reduced PTEN expression by comparison with corresponding normal tissue. In our opinion, a minimal percentage of positive cells should be taken into account when assessing PTEN expression in a tumor. In a study comparing different immunostaining in TMA and full sections of vulvar cancer patients, a minimal percentage of positive cells was also taken into account, and this study resulted in a good reproducibility of immunostaining on TMA [18].

Experimental data also indicate a role for loss of PTEN in determining the metastatic potential of tumors. In a study using a benign melanocytic hyperplasia mice model, silencing PTEN leads to the development of melanoma and metastases to lymph nodes and lungs [19]. In a study of colorectal cancer patients, Sawai et al [20] observed an association between reduced PTEN expression and liver

Table 4 Disease-specific survival (Cox regression analysis)

	Univariate			Multivariate		
	HR	(95% CI)	*P*	HR	(95% CI)	*P*
Age	1.02	1.00-1.04	.055	#		
Stage ≥IB2	2.34	1.38-3.98	.002	#		
Squamous	0.72	0.40-1.29	.266	#		
Poor differentiation	1.73	1.01-2.95	.045	1.91	1.12-3.26	.018
Lymphangioinvasion	2.38	1.32-4.26	.004	#		
Infiltration depth ≥10 mm	2.00	1.15-3.49	.014	#		
Positive lymph nodes	5.76	3.30-10.04	<.001	6.11	3.46-10.77	<.001
Tumor diameter ≥4 cm	2.45	1.44-4.16	.001	#		
EGFR	1.24	0.69-2.22	.468	#		
pEGFR	0.81	0.39-1.66	.556	#		
PTEN	0.61	0.33-1.14	.120	#		
pAKT	0.71	0.17-2.93	.638	#		
pERK	0.05	0.0-15.02	.298	#		

Abbreviation: # = not included in final analysis.

metastases. Activation of receptor tyrosine kinases such as epidermal growth factor receptor, Her2/neu, and insulin-like growth factor receptor 1 results in recruitment of PI3K [9]. The direct product of PI3K is phosphatidylinositol-3,4,5-triphosphate (PIP3), and PIP3 is the primary target of PTEN [21]. Loss of PTEN function results in accumulation of PIP3 and thereby deletes activation of its downstream targets, the AKT pathway. Activation of the AKT pathway may cause cell cycle progression, cell survival, cell spreading and motility, and angiogenesis [9]. In our study, no relation between loss of PTEN and activation of the AKT pathway was found. Our low percentage (5.3%) of pAKT-positive cases is in contrast to previous studies in cervical cancer that used the same antibody and staining protocol but observed 29% to 94% pAKT-positive cases [22-24]. A major difference between these studies and our study is that we assessed pAKT in a much larges series (310 vs 31) of early-stage cervical cancer patients.

Loss of PTEN can be due to mutations, deletions, gene promoter methylation, or microRNAs (miRs) [25-28]. Mutations and deletions of *PTEN* are rare events in cervical cancer [16,22,29]. In a study by Yang et al, *PTEN* methylation was observed in 20 (15.7%) of 127 cervical cancers, whereas Cheung et al [16] reported *PTEN* methylation in 36 (58%) of 62 of squamous cell cervical cancers. They found no PTEN expression in 3 of 10 *PTEN* methylation–negative cases and in 0 of 10 *PTEN* methylation–positive cases. Preliminary data from our cases show *PTEN* gene promoter methylation in 4 (21%) of 19 cases. No PTEN immunostaining was observed in these 4 *PTEN* methylation–positive cases (data not shown). Loss of PTEN expression could also occur via miRs. Several miRs, such as miR-21 and miR-214, can target PTEN [27,28]. Both miRs appear to be up-regulated in cervical cancer [30,31], but a relation with PTEN loss has not been reported. It might be that loss of PTEN expression can only partially be explained by down-regulation via miRs.

A downstream component of the PI3K/AKT pathway, known as the mammalian target of rapamycin (mTOR) pathway, is up-regulated in many cancers. As a consequence of PTEN loss, activation of the mTOR pathway may occur. As shown in in vitro and in vivo experiments, cells without PTEN are more sensitive to mTOR inhibitors (rapamycin) [32,33]. These mTOR inhibitors might provide efficacious additional therapy in cervical cancer patients with an unfavorable prognosis and loss of PTEN.

Our study indicates a strong relation between squamous cell carcinomas and EGFR staining, which was previously reported in cervical cancer by Kersemaekers et al [11]. In their study, EGFR overexpression was observed in 54% (73/136) cervical cancer cases and was associated with reduced disease-free and reduced overall survival in surgically treated cervical cancer patients [11]. These findings could not be confirmed in our large series of cervical cancer patients, where 32.1% of cases overexpressed EGFR. One explanation might be the use of a different antibody. Another possibility is that our study included a larger percentage of adenocarcinomas (28% vs 9%), and as is shown in our study, EGFR expression is highly associated with squamous cell carcinoma.

In conclusion, in early-stage cervical cancer, loss of PTEN expression is associated with pelvic lymph node metastasis, suggesting that PTEN is one of the tumor suppressor genes affecting pelvic lymph node metastasis in early-stage cervical cancer. Overall, however, the EGFR pathway does not appear to have prognostic impact in surgically treated early-stage cervical cancer.

References

[1] Fuller Jr AF, Elliott N, Kosloff C, Hoskins WJ, Lewis Jr JL. Determinants of increased risk for recurrence in patients undergoing radical hysterectomy for stage IB and IIA carcinoma of the cervix. Gynecol Oncol 1989;33:34-9.

[2] Gallion HH, van Nagell Jr JR, Donaldson ES, et al. Combined radiation therapy and extra-fascial hysterectomy in the treatment of stage IB barrel-shaped cervical cancer. Cancer 1985;56:262-5.

[3] Matsuyama T, Inoue I, Tsukamoto N, et al. Stage Ib, IIa, and IIb cervix cancer, postsurgical staging, and prognosis. Cancer 1984;54: 3072-7.

[4] Sevin BU, Nadji M, Lampe B, et al. Prognostic factors of early stage cervical cancer treated by radical hysterectomy. Cancer 1995; 76(10 Suppl):1978-86.

[5] Creasman WT, Kohler MF. Is lymph vascular space involvement an independent prognostic factor in early cervical cancer? Gynecol Oncol 2004;92:525-9.

[6] Sakuragi N. Up-to-date management of lymph node metastasis and the role of tailored lymphadenectomy in cervical cancer. Int J Clin Oncol 2007;12:165-75.

[7] Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001;2:127-37.

[8] Blanco-Aparicio C, Renner O, Leal JF, Carnero A. PTEN, more than the AKT pathway. Carcinogenesis 2007;28:1379-86.

[9] Sansal I, Sellers WR. The biology and clinical relevance of the PTEN tumor suppressor pathway. J Clin Oncol 2004;22:2954-63.

[10] Hale RJ, Buckley CH, Gullick WJ, Fox H, Williams J, Wilcox FL. Prognostic value of epidermal growth factor receptor expression in cervical carcinoma. J Clin Pathol 1993;46:149-53.

[11] Kersemaekers AM, Fleuren GJ, Kenter GG, et al. Oncogene alterations in carcinomas of the uterine cervix: overexpression of the epidermal growth factor receptor is associated with poor prognosis. Clin Cancer Res 1999;5:577-86.

[12] Kristensen GB, Holm R, Abeler VM, Trope CG. Evaluation of the prognostic significance of cathepsin D, epidermal growth factor receptor, and c-erbB-2 in early cervical squamous cell carcinoma. An immunohistochemical study. Cancer 1996;78:433-40.

[13] Lee JS, Choi YD, Lee JH, et al. Expression of PTEN in the progression of cervical neoplasia and its relation to tumor behavior and angiogenesis in invasive squamous cell carcinoma. J Surg Oncol 2006;93:233-40.

[14] Nijhuis ER, Nijman HW, Oien KA, et al. Loss of MSH2 protein expression is a risk factor in early stage cervical cancer. J Clin Pathol 2007;60:824-30.

[15] de Graeff P, Crijns AP, Ten Hoor KA, et al. The ErbB signalling pathway: protein expression and prognostic value in epithelial ovarian cancer. Br J Cancer 2008;99:341-9.

[16] Cheung TH, Lo KW, Yim SF, et al. Epigenetic and genetic alternation of PTEN in cervical neoplasm. Gynecol Oncol 2004;93:621-7.

[17] Wiley HS. Trafficking of the ErbB receptors and its influence on signaling. Exp Cell Res 2003;284:78-88.

[18] Fons G, van d V, Burger M, ten KF. Validation of tissue microarray technology in vulvar cancer. Int J Gynecol Pathol 2009;28:76-82.

[19] Dankort D, Curley DP, Cartlidge RA, et al. Braf(V600E) cooperates with Pten loss to induce metastatic melanoma. Nat Genet 2009;41: 544-52.

[20] Sawai H, Yasuda A, Ochi N, et al. Loss of PTEN expression is associated with colorectal cancer liver metastasis and poor patient survival. BMC Gastroenterol 2008:856.

[21] Maehama T, Dixon JE. The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J Biol Chem 1998;273:13375-8.

[22] Bertelsen BI, Steine SJ, Sandvei R, Molven A, Laerum OD. Molecular analysis of the PI3K-AKT pathway in uterine cervical neoplasia: frequent PIK3CA amplification and AKT phosphorylation. Int J Cancer 2006;118:1877-83.

[23] Faried LS, Faried A, Kanuma T, et al. Predictive and prognostic role of activated mammalian target of rapamycin in cervical cancer treated with cisplatin-based neoadjuvant chemotherapy. Oncol Rep 2006;16: 57-63.

[24] Kim TJ, Lee JW, Song SY, et al. Increased expression of pAKT is associated with radiation resistance in cervical cancer. Br J Cancer 2006;94:1678-82.

[25] Parsons DW, Wang TL, Samuels Y, et al. Colorectal cancer: mutations in a signalling pathway. Nature 2005;436:792.

[26] Vivanco I, Sawyers CL. The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer 2002;2:489-501.

[27] Talotta F, Cimmino A, Matarazzo MR, et al. An autoregulatory loop mediated by miR-21 and PDCD4 controls the AP-1 activity in RAS transformation. Oncogene 2008.

[28] Yang H, Kong W, He L, et al. MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN. Cancer Res 2008;68:425-33.

[29] Su TH, Chang JG, Perng LI, et al. Mutation analysis of the putative tumor suppressor gene PTEN/MMAC1 in cervical cancer. Gynecol Oncol 2000;76:193-9.

[30] Lee JW, Choi CH, Choi JJ, et al. Altered MicroRNA expression in cervical carcinomas. Clin Cancer Res 2008;14:2535-42.

[31] Lui WO, Pourmand N, Patterson BK, Fire A. Patterns of known and novel small RNAs in human cervical cancer. Cancer Res 2007;67: 6031-43.

[32] Neshat MS, Mellinghoff IK, Tran C, et al. Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc Natl Acad Sci U S A 2001;98:10314-9.

[33] Podsypanina K, Lee RT, Politis C, et al. An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/− mice. Proc Natl Acad Sci U S A 2001;98:10320-5.